Intellia Therapeutics Inc... (NTLA)
NASDAQ: NTLA
· Real-Time Price · USD
24.75
-0.16 (-0.64%)
At close: Oct 17, 2025, 3:59 PM
25.00
1.01%
After-hours: Oct 17, 2025, 07:55 PM EDT
Intellia Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | 57.88M | 36.27M | 52.12M | 33.05M |
Cost of Revenue | 10.29M | 8.98M | 7.57M | 6.89M |
Gross Profit | 47.59M | 27.3M | 44.55M | 26.16M |
Operating Income | -534.26M | -515.29M | -458.16M | -267.85M |
Interest Income | 47.81M | 49.83M | 8.54M | 1.28M |
Pretax Income | -519.02M | -481.19M | -474.19M | -267.89M |
Net Income | -519.02M | -481.19M | -474.19M | -267.89M |
Selling & General & Admin | 125.83M | 116.5M | 90.31M | 71.1M |
Research & Development | 466.31M | 435.07M | 419.98M | 229.81M |
Other Expenses | -10.29M | -8.98M | -7.57M | -6.89M |
Operating Expenses | 581.86M | 542.59M | 502.71M | 294.01M |
Interest Expense | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 592.14M | 551.57M | 510.29M | 300.9M |
Income Tax Expense | n/a | n/a | 16.02M | -8.17M |
Shares Outstanding (Basic) | 98.85M | 88.77M | 76.97M | 70.89M |
Shares Outstanding (Diluted) | 98.85M | 88.77M | 76.97M | 70.89M |
EPS (Basic) | -5.25 | -5.42 | -6.16 | -3.78 |
EPS (Diluted) | -5.25 | -5.42 | -6.16 | -3.78 |
EBITDA | -523.98M | -506.31M | -450.59M | -260.96M |
EBIT | -534.26M | -515.29M | -458.16M | -267.85M |
Depreciation & Amortization | 10.29M | 8.98M | 7.57M | 6.89M |
Source: Financial Modeling Prep. Financial Sources.